Departamento de Química, Unidad Departamental de Química Analítica, Universidad de La Laguna (ULL), La Laguna, Tenerife, 38206, Spain.
J Chromatogr A. 2018 Jul 20;1559:102-111. doi: 10.1016/j.chroma.2017.04.061. Epub 2017 May 1.
The IL-based surfactant octylguanidinium chloride (CGu-Cl) was designed and synthetized with the purpose of obtaining a less harmful surfactant: containing guanidinium as core cation and a relatively short alkyl chain. Its interfacial and aggregation behavior was evaluated through conductivity and fluorescence measurements, presenting a critical micelle concentration value of 42.5 and 44.6mmolL, respectively. Cytotoxicity studies were carried out with CGu-Cl and other IL-based and conventional surfactants, specifically the analogue 1-octyl-3-methylimidazolium chloride (CMIm-Cl), and other imidazolium- (CMIm-Br) and pyridinium- (CPy-Cl) based surfactants, together with the conventional cationic CTAB and the conventional anionic SDS. From these studies, CGu-Cl was the only one to achieve the classification of low cytotoxicity. An in situ dispersive liquid-liquid microextraction (DLLME) method based on transforming the water-soluble CGu-Cl IL-based surfactant into a water-insoluble IL microdroplet via a simple metathesis reaction was then selected as the extraction/preconcentration method for a group of 6 personal care products (PCPs) present in cosmetic samples. The method was carried out in combination with high-performance liquid chromatography (HPLC) and diode array detection (DAD). The method was properly optimized, requiring the use of only 30μL of CGu-Cl for 10mL of aqueous sample with a NaCl content of 8% (w/v) to adjust the ionic strength and pH value of 5. The metathesis reaction required the addition of the anion exchange reagent (bis[(trifluoromethyl)sulfonyl]imide - 1:1 molar ratio), followed by vortex and centrifugation, and dilution of the final microdroplet up to 60μL with acetonitrile before the injection in the HPLC-DAD system. The optimum in situ DLLME-HPLC-DAD method takes ∼10min for the extraction step and ∼22min for the chromatographic separation, with analytical features of low detection limits: down to 0.4μgL; high reproducibility: with RSD values lower than 10% (intra-day) and 16% (inter-day) for a spiked level of 15μgL; and an average enrichment factor of 89. The requirement of low volumes (30μL) of a low cytotoxic IL-based surfactant allows the method to be considered less harmful than other common analytical microextraction approaches.
基于 IL 的表面活性剂辛基胍盐酸盐(CGu-Cl)是为了获得一种危害性较小的表面活性剂而设计和合成的:它的核心阳离子为胍,烷基链相对较短。通过电导率和荧光测量评估了其界面和聚集行为,临界胶束浓度值分别为 42.5 和 44.6mmol/L。用 CGu-Cl 及其他基于 IL 和常规的表面活性剂进行了细胞毒性研究,具体的是类似物 1-辛基-3-甲基咪唑氯(CMIm-Cl),以及其他咪唑基(CMIm-Br)和吡啶基(CPy-Cl)表面活性剂,以及常规的阳离子 CTAB 和常规的阴离子 SDS。从这些研究中可以看出,只有 CGu-Cl 被归为低细胞毒性。然后选择了一种基于原位分散液-液微萃取(DLLME)的方法,通过简单的复分解反应将水溶性 CGu-Cl 基于 IL 的表面活性剂转化为不溶于水的 IL 微滴,作为一组存在于化妆品样品中的 6 种个人护理产品(PCPs)的萃取/预浓缩方法。该方法与高效液相色谱(HPLC)和二极管阵列检测(DAD)相结合。该方法经过适当优化,仅需 30μL 的 CGu-Cl 即可用于 10mL 含 8%(w/v)NaCl 的水样品,以调节离子强度和 pH 值至 5。复分解反应需要加入阴离子交换试剂(双(三氟甲基磺酰基)亚胺-1:1 摩尔比),然后涡旋和离心,最后用乙腈将最终的微滴稀释至 60μL,再注入 HPLC-DAD 系统。最佳的原位 DLLME-HPLC-DAD 方法的萃取步骤约需 10min,色谱分离约需 22min,具有低检测限的分析特点:低至 0.4μg/L;高重现性:日内 RSD 值低于 10%,15μg/L 加标水平的日间 RSD 值低于 16%;平均富集因子为 89。低细胞毒性 IL 基表面活性剂的低体积(30μL)要求使该方法被认为比其他常见的分析微萃取方法的危害性更小。